Description: CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Home Page: www.cansinotech.com
401-420, Biomedical Park
Tianjin,
China
Phone:
400 922 2099
Officers
| Name | Title |
|---|---|
| Dr. Xuefeng Yu Ph.D. | Co-Founder, Chairman, CEO & GM |
| Dr. Tao Zhu Ph.D. | Co-Founder, Exec. Director, Deputy GM & Chief Scientific Officer |
| Dr. Dongxu Qiu MBA, Ph.D. | Co-Founder, Exec. VP, Exec. Director & Deputy GM |
| Ms. Xi Luo | Chief Financial Officer |
| Dr. Shou-Bai Chao | Exec. Director, COO & Deputy GM |
| Mr. Chunlin Xin | Sr. Director of New Technology Department |
| Mr. Yonghui Wu | VP of Marketing |
| Ms. Jing Wang | Chief Commercial Officer, Deputy GM & Exec. Director |
| Mr. Ming King Chiu FCIS, FCS | Joint Company Sec. |
Exchange: SHG
Country: CN : China
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 37.1975 |
| Price-to-Book MRQ: | 5.7161 |
| Price-to-Sales TTM: | 16.716 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1946 |